Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment

Endocrine-Related Cancer

Volumn 10, Issue 1, 2003, Pages 1-21

  Normanno, N ^a   Bianco, C ^b   De Luca, A ^a   Maiello, M R ^a   Salomon, D S ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMPHIREGULIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETACELLULIN; CANERTINIB; CETUXIMAB; CISPLATIN; CL 1033; CRIPTIN; CYTOTOXIC AGENT; DOCETAXEL; EB 569; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LAPATINIB; LIGAND; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PROTEIN CRIPTO 1; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TOMOREGULIN; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG RECEPTOR BINDING; HEAD AND NECK CARCINOMA; HEART DISEASE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CARCINOMA; PATHOGENESIS; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RASH; REVIEW; SIDE EFFECT; SKIN CARCINOMA; SKIN DISEASE; STOMATITIS; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LIGANDS; NEOPLASMS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 1642421130     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100001     Document Type: Review

References (204)

1. Aaronson SA 1991 Growth factors and cancer. Science 254 1146-1153.
2. Abbruzzese J, Rosenberg A, Xiong Q, LoBuglio A, Schmidt W, Wolff R, Needle M & Waksal H 2001 Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proceedings of the American Society for Clinical Oncology 20 130.
3. Albanell J, Cordony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J & Baselga J 2001 Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Research 61 6500-6510.
4. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI & Baselga J 2002 Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Journal of Clinical Oncology 20 110-124.
5. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP & Kraus MH 1995 Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10 1813-1821.
6. Anderson NG, Ahmad T, Chan K, Dobson R & Bundred NJ 2001 ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. International Journal of Cancer 94 774-782.
7. Anido J, Albanell J, Rojo F, Arribas J, Averbuch S & Baselga J 2002 ZD1839 (Iressa), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2 overexpressing breast cancer cells. Proceedings of the American Association of Cancer Research 43 783.
8. cerbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Research 54 3758-3765.
9. Arteaga CL, Ramsey TT, Shawver LK & Guyer CA 1997 Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. Journal of Biological Chemistry 272 23247-23254.
10. Baly DL, Wirth CM, Allison DA, Gilkerson E, Hotaling TE & Fox JA 1997 Development and characterization of a rhuMAb HER2 antibody ADCC assay for clinical evaluation of cytotoxic potency. Proceedings of the American Association of Cancer Research 38 27.
11. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Aston SE, Curry BJ, Scarlett L, Henthom L & Richards L 2001 Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic and Medicinal Chemistry Letters 11 1911-1914.
12. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH & Mendelsohn J 1993 Anti-tumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. Journal of the National Cancer Institute 85 1327-1333.
13. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC & Norton L 1996 Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology 14 737-744.
14. Baselga J, Norton L, Albanell J, Kim YM & Mendelsohn J 1998 Recombinant humanized anti-HER2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Research 58 2825-2831.
15. Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox AM, Kaye SB, Kieback DG, Harris A & Ochs J 2000a Continuous administration of ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proceedings of the American Society for Clinical Oncology 19 177.
16. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H & Mendelsohn J 2000b Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal of Clinical Oncology 18 904-914.
17. Baulida J, Kraus MH, Alimandi M, Di Fiore PP & Carpenter G 1996 All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. Journal of Biological Chemistry 271 5251-5257.
18. Bei R, Pompa G, Vitolo D, Moriconi E, Ciocci L, Quaranta M, Frati L, Kraus MH & Muraro R 2001 Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. Journal of Pathology 195 343-348.
19. Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR & Ciardiello F 2000 Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clinical Cancer Research 6 4343-4350.
20. Bonner JA, Ezekiel MP, Robert F, Meredith RF, Spencer SA & Waksal HW 2000 Continued response following treatment with IMC-C225, an EGFR MoAb, combined with RT in advanced head and neck malignancies. Proceedings of the American Society for Clinical Oncology 19 4.
21. Brandt R, Wong AML & Hynes NE 2001 Mammary glands reconstituted with Neu/ErbB-2 transformed HC-11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene 20 5459-5465.
22. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Abbruzzese J, Evans DB, Hicklin DJ & Radinsky R 2000a Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanism. Clinical Cancer Research 6 1936-1948.
23. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Rdinsky R & Fidler IJ 2000b Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Research 60 2926-2935.
24. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulamn LN & Winer EP 2001 Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 19 2722-2730.
25. Campbell ID & Bork P 1993 Epidermal growth factor-like modules. Current Opinion in Structural Biology 3 385-392.
26. Campiglio M, Normanno N, Olgiati C, Locatelli A, Fumagalli M, Viganò L, Gianni L & Menard S 2002 Blockage of the EGF-receptor by ZD1839 resulted in growth inhibition of human breast cancer cell lines with up-regulation of the activated EGFR and/or HER2. Proceedings of the American Association of Cancer Research 43 603.
27. Carpenter G & Cohen S 1990 Epidermal growth factor. Journal of Biological Chemistry 265 7709-7712.
28. HER2 antibody for human cancer therapy. PNAS 89 4285-4289.
29. Casamassimi A, De Luca A, Agrawal S, Stromberg K, Salomon DS & Normanno N 2000 EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. Annals of Oncology 11 319-325.
30. Chen X, Yeung TK & Wang Z 2000 Enhanced drug resistance in cells coexpressing erbB2 with EGF receptor or erbB3. Biochemical and Biophysical Research Communications 277 757-763.
31. Chow NH, Chan SH, Tzai TS, Ho CL & Liu HS 2001 Expression profile of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clinical Cancer Research 7 1957-1962.
32. Christen RD, Hom DK, MacLeod CL, Hafstrom L & Howell SB 1990 Epidermal growth factor regultes the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. Journal of Clinical Investigation 86 1632-1640.
33. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR & Tortora G 1996 Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. Journal of the National Cancer Institute 88 1770-1776.
34. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR & Tortora G 1999 Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clinical Cancer Research 5 909-916.
35. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR & Tortora G 2000 Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clinical Cancer Research 6 2053-2063.
36. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR & Tortora G 2001 Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clinical Cancer Research 7 1459-1465.
37. Cobleigh MA, Vogel CL, Tripathy D, Robert JN, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G & Slamon DJ 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology 17 2639-2648.
38. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP & Zhang K 1996 The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. Journal of Biological Chemistry 271 30897-30903.
39. Cohen EE, Rosen F, Dekker A, Bajda C, Stenson K, Shulman KL, Lamont E, Kozloff M & Vokes EE 2002 Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proceedings of the American Society for Clinical Oncology 21 225.
40. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J, Chien KR & Lee K-F 2002 ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine 8 459-465.
41. Crovello CS, Lai C, Cantley LC & Carraway KL 1998 Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2. Journal of Biological Chemistry 273 26954-26961.
42. D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR, Iaffaioli VR, Salomon DS & Normanno N 2002 Transforming growth factor α, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. International Journal of Oncology 21 941-948.
43. De Luca A, Selvam MP, Sandomenico C, Pepe S, Bianco AR, Ciardiello F, Salomon DS & Normanno N 1997 Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. International Journal of Cancer 73 277-282.
44. De Luca A, Casamassimi A, Selvam MP, Losito S, Ciardiello F, Agrawal S, Salomon DS & Normanno N 1999 EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. International Journal of Cancer 80 589-594.
45. De Luca A, Arra C, D'Antonio A, Casamassimi A, Losito S, Ferraro P, Ciardiello F, Salomon DS & Normanno N 2000 Simultaneous blockade of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene 19 5863-5871.
46. Derynck R 1992 The physiology of transforming growth factor-alpha. Cancer Research 58 27-52.
47. Dickstein B, Valverius EM, Wosikowski K, Saceda M, Pearson JW, Martin MB & Bates SE 1993 Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. Journal of Cellular Physiology 157 110-118.
48. Dickstein BM, Wosikowski K & Bates SE 1995 Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Molecular and Cellular Endocrinology 110 205-211.
49. Dixit M, Yang J-L, Poirier MC, Price JO, Andrews PA & Arteaga CL 1997 Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. Journal of the National Cancer Institute 89 365-373.
50. Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH & Perez-Soler R 2000 EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clinical Cancer Research 6 193-202.
51. Drucker BJ, Schwartz L, Marion S & Motzer R 2002 Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma. Proceedings of the American Society for Clinical Oncology 21 181.
52. Elenius K, Paul S, Allison G, Sun J & Klagsbrun M 1997 Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO Journal 16 1268-1278.
53. Elenius K, Choi CJ, Paul S, Nishi E & Klagsbrun M 1999 Characterisation of a naturally occurring ErbB-4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18 2607-2615.
54. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pustzai L, Cristofanili M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL & Hortobagyi GN 2002 Phase II studies of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20 1800-1808.
55. Fan Z, Baselga J, Masui H & Mendelsohn J 1993 Anti-tumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminodichloroplatinum on well estabilished A431 cell xenografts. Cancer Research 53 4637-4642.
56. Fan Z, Lu Y, Wu X & Mendelsohn J 1994 Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry 269 27595-27602.
57. Fan Z, Shang BY, Lu Y, Chou JL & Mendelsohn J 1997 Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clinical Cancer Research 3 1943-1948.
58. Ferry D, Hammond L, Ranson M, Kris MG, Miller V, Murray P, Tullo A, Feyereislova A, Averbuch S & Rowinsky E 2000 Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study. Proceedings of the American Society for Clinical Oncology 19 3.
59. Finkler N, Gordon A, Crozier M, Edwards R, Figueroa J, Garcia A, Hainsworth J, Irwin D, Silberman S, Allen L, Ferrante K, Fisher D & Nadler P 2001 Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proceedings of the American Society for Clinical Oncology 20 208.
60. Fontanini G, De Laurentiis M, Vignati S, Chinè S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F 1998 Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clinical Cancer Research 4 241-249.
61. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW & Korc M 1995 Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clinical Cancer Research 1 1413-1420.
62. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, Korc M & Buchler MW 1999 Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not for c-erbB-2 and c-erbB-3. World Journal of Surgery 23 1010-1018.
63. Fry DW 2000 Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anti-Cancer Drug Design 15 3-16.
64. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste JF, Kudo S, Averbuch S, Macleod A, Feyereislova A & Baselga J 2002 Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proceedings of the American Society for Clinical Oncology 21 298.
65. Gasparini G, Gullick WJ, Maluta S, Dalla Palma P, Caffo O, Leonardi E, Boracchi P, Pozza F, Lemoine NR & Bevilacqua P 1994 c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma - an immunocytochemical study. European Journal of Cancer 30A 16-22.
66. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD & Lunec J 1997 Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Research 57 3272-3280.
67. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, MacLeod C & Mendelsohn J 1984 Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. Journal of Biological Chemistry 259 7755-7760.
68. Gilmour LM, Macleod KG, McCaig A, Gullick WJ, Smyth JF & Langdon SP 2001 Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Research 61 2169-2176.
69. Goldstein NI, Prewett M, Zuklys K, Rockwell P & Mendelsohn J 1995 Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical Cancer Research 1 1311-1318.
70. Gonzalez-Larriba JL, Giaccone G, van Osterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, van der Vijgh WJF, Smith R, Fandi A & Averbuch S 2002 ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumors: final results of a phase I trial. Proceedings of the American Society for Clinical Oncology 21 95.
71. Goss G, Hirte H, Batist G, Stewart D, Miller W, Lorimer I, Abugaber A, Matthews S & Seymour L 2000 NCIC CTG IND. 122: a two part phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839. Proceedings of the American Society for Clinical Oncology 19 225.
72. Graber HU, Friess H, Kaufmann B, Willi D, Zimmermann A, Korc M & Buchler MW 1999 ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. International Journal of Cancer 84 24-27.
73. Graus-Porta D, Beerli RR, Daly JM & Hynes NE 1997 ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling. EMBO Journal 16 1647-1655.
74. Gullick WJ 2001 The Type 1 growth factor receptors and their ligands considered as a complex system. Endocrine-Related Cancer 8 75-82.
75. Guy PM, Platkp JV, Cantley LC, Cerione RA & Carraway KL 1994 Insect cell-expressed p180erbB-3 possesses an impaired tyrosine kinase activity. PNAS 91 8132-8136.
76. Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC & Yarden Y 1999 Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 18 2681-2689.
77. Harlozinska A, Bar JK, Wenderski R & Bebenek M 1996 Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes. In Vivo 10 217-222.
78. Harris AL, Nicholson S, Sainsbury JRC, Famdon J & Wright C 1989 Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. Journal of Steroid Biochemistry 34 123-131.
79. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S & Rowinski EK 2001 Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Journal of Clinical Oncology 19 3267-3279.
80. Hidalgo M, Erlichman C, Rowinski EK, Koepp-Norris J, Jensen K, Boni J, Korth-Bradley J, Quinn S & Zacharchuk C 2002 Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Proceedings of the American Society for Clinical Oncology 21 17.
81. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M & Ono M 2002 ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Research 62 2554-2560.
82. Hong WK, Arquette M, Nabell L, Needle M, Waksal HW & Herbst RS 2001 Efficacy and safety of the anti-epidermal growth factor receptor antibody (EGFR) IMC-C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proceedings of the American Society for Clinical Oncology 20 224.
83. Huang SM & Harari PM 2000 Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clinical Cancer Research 6 2166-2174.
84. Huang SM, Bock JM & Harari PM 1999 Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Research 59 1935-1940.
85. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM & Ullrich A 1989 p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molecular and Cellular Biology 9 1165-1172.
86. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R & Dinney CP 2000 Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clinical Cancer Research 6 4874-4884.
87. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M & Matsuura N 2001 Expression and clinical significance of erbB receptor family in hepatocellular carcinoma. British Journal of Cancer 84 1377-1383.
88. Jarine PA, Ostler PA, Lucca J, Fidias P, Skarin AT, Lynch TJ & Johnson BE 2002 Zd1839 ('Iressa') shows antitumor activity in patients with recurrent non-small-cell lung cancer treated on a compassionate use protocol. Proceedings of the American Society for Clinical Oncology 21 319.
89. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH & Mendelsohn J 1983 Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. PNAS 80 1337-1341.
90. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N & Neoptolemos JP 2000 K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21 (WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. International Journal of Cancer 89 469-474.
91. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y & Sela M 1997 A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 14 2099-2109.
92. Klohs WD, Fry DW & Kraker AJ 1997 Inhibitors of tyrosine kinase. Current Opinion in Oncology 9 562-568.
93. Kris MG, Natale RB, Herbst RS, Lynch TJJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmenr JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J & Kay A 2002 A phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum and docetaxel based regimens (IDEAL 2). Proceedings of the American Society for Clinical Oncology 21 292.
94. Kroning R, Jones JA, Hom DK, Chuang CC, Sanga R, Los G, Howell SB & Christen RD 1995 Enhancement of drug sensitivity of human malignancies by epidermal growth factor. British Journal of Cancer 72 615-620.
95. Kumar R, Shepard HM & Mendelsohn J 1991 Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Molecular and Cellular Biology 11 979-986.
96. kip1 complex formation: receptor overexpression does not determine growth dependency. Molecular and Cellular Biology 20 3210-3223.
97. c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth and Differentiation 5 1367-1372.
98. Laurie SA, Miller VA, Johnson D, Ng KK, Heelan RT, Pizzo BA, Perez WJ, Kris MG, Ochs J & Averbuch S 2000 Pilot trial of ZD1839 ('Iressa'), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin and paclitaxel in previously untreated advanced non-small-cell lung cancer (NSCLC). Lung Cancer 29 (Suppl 1) 71.
99. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ & Hurst HC 1992 Expression of the ERBB3 product in breast cancer. British Journal of Cancer 66 1116-1121.
100. Lenferink AEG, Pinkas-Kramarski R, Van de Poll ML, van Vugt MJH, Klapper LN, Tzahar E, Waterman H, Sela M, Van Zoelen EJ & Yarden Y 1998 Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO Journal 17 3385-3397.
101. kip1 and cyclin D1 through multiple signaling pathways. Cancer Research 61 6583-6591.
102. Liem AK, Cheng H, Quan E, Ucar K, Al-Jazayrly G, Barton C, Cloo L & Tchekmedyian S 2002 Expanded access single institution clinical program experience with ZD1839 (Iressa) for patients with advanced non-small-cell lung cancer (NSCLC). Proceedings of the American Society for Clinical Oncology 21 222b.
103. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL & Milano G 2002a Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. British Journal of Cancer 86 819-827.
104. Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P & Milano G 2002b Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumor cells on the antiproliferative effect of ZD1839 ('Iressa'). British Journal of Cancer 86 1518-1523.
105. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX & DuBois RN 2001 Targeting cycloxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120 1713-1719.
106. Mason S & Gullick WJ 1995 Type 1 growth factor receptors: an overview of recent developments. The Breast 4 11-18.
107. Massagué J & Pandiella A 1993 Membrane-anchored growth factors. Annual Review of Biochemistry 62 515-541.
108. Maurer CA, Friess H, Kretshmann B, Zimmermann A, Stauffer A, Bauer HU, Korc M & Buchler MW 1998 Increased expression of erbB-3 in colorectal cancer is associated with concomitant increase in the level of erbB-2. Human Pathology 29 771-777.
109. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J & Fan Z 2000 In vivo enhancement of tumor radio-response by C225 antiepidermal growth factor receptor antibody. Clinical Cancer Research 6 701-708.
110. Miller VA, Johnson D, Heelan RT, Pizzo BA, Perez WJ, Bass A, Kris MG, Ochs J & Averbuch S 2001 A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small lung cancer (NSLC). Proceedings of the American Society for Clinical Oncology 20 326.
111. Moasser MM, Basso A, Averbuch SD & Rosen N 2001 The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Research 61 7184-7188.
112. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J & Baselga J 2001 Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Research 61 4744-4749.
113. Montgomery RB, Guzman J, O'Rourke DM & Stahl WL 2000 Expression of oncogenic epidermal growth factor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. Journal of Biological Chemistry 275 17358-17363.
114. Morin MJ 2000 From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19 6574-6583.
115. Motoyama A, Hynes NE & Lane HA 2002 The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor related peptides. Cancer Research 62 3151-3158.
116. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF & Arteaga CL 2001 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Research 61 8887-8895.
117. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A & Miller P 1997 Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Research 57 4838-4848.
118. Muthuswamy SK, Gilman M & Brugge JS 1999 Controlled dimerization of ErbB receptors provids evidence for differential signaling by homo- and heterodimers. Molecular and Cellular Biology 19 6845-6857.
119. Myers RB, Srivastava S, Oelsclager DK & Grizzle WE 1994 Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Journal of the National Cancer Institute 86 1140-1145.
120. Naidu R, Yadav M, Nair S & Kutty MK 1998 Expression of c-erbB-3 protein in primary breast carcinoma. British Journal of Cancer 78 1386-1390.
121. Nakagawa K, Yamamoto N, Kudoh S, Negoro S, Takeda K, Tamura T & Fukuoka M 2000 A phase I intermittent dose escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours. Proceedings of the American Society for Clinical Oncology 19 183.
122. Normanno N, Kim N, Wen D, Smith K, Harris AL, Plowman GD, Colletta G, Ciardiello F & Salomon DS 1995 Expression of messenger RNA for amphiregulin, heregulin and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Research and Treatment 35 293-297.
123. Normanno N, Bianco C, Damiano V, de Angelis E, Selvam MP, Grassi M, Magliulo G, Tortora G, Bianco AR, Mendelsohn J, Salomon DS & Ciardiello F 1996 Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clinical Cancer Research 2 601-609.
124. Normanno N, Bianco C, De Luca A & Salomon DS 2001 The role of EGF-related peptides in tumor growth. Frontiers in Bioscience 6 d685-d707.
125. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS & Menard S 2002 Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Annals of Oncology 13 65-72.
126. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B & Hynes NE 1998 ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Molecular and Cellular Biology 18 5042-5051.
127. Olayioye MA, Beuvink I, Korsch K, Daly JM & Hynes NE 1999 ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrosine kinases. Journal of Biological Chemistry 274 17209-17218.
128. Olayioye MA, Neve RM, Lane HA & Hynes NE 2000 The ErbB signalling network: receptor dimerisation in development and cancer. EMBO Journal 19 3159-3167.
129. Orr MS, O'Connor PM & Kohn KW 2000 Effects of c-erbB-2 overexpression on the drug sensitivities of normal human mammary epithelial cells. Journal of the National Cancer Institute 92 987-994.
130. Osaki A, Toi M, Yamada H, Kawami H, Kuroi K & Toge T 1992 Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. American Journal of Surgery 164 323-326.
131. Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M, De Placido S, Giordano T, Merino M, Salomon DS, Gullick WJ, Pettinato G, Schnitt SJ, Bianco AR & Ciardiello F 1996 Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and cripto in human normal and malignant breast tissue. International Journal of Cancer 65 51-56.
132. Pegram MD, Baly D, Wirth C, Gilkerson E, Slamon DJ, Sliwkowski MX, Bauer K & Fox JA 1997a Antibody dependent cell-mediated cytotoxicity in breast cancer patients in Phase HI clinical trials of a humanized anti-HER2 antibody. Proceedings of the American Association of Cancer Research 38 602.
133. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ & Slamon DJ 1997b The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15 537-547.
134. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga J, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA & Slamon DJ 1998 Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Journal of Clinical Oncology 16 2659-2671.
135. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F & Slamon D 1999 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18 2241-2251.
136. Peles E & Yarden Y 1993 Neu and its ligands: from an oncogene to neural factors. Bioessays 15 815-824.
137. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante K, Allen L, Nadler P & Bonomi P 2001 A phase H trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing non-small-cell lung cancer (NSCLC). Proceedings of the American Society for Clinical Oncology 20 310.
138. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R & Dinney CP 1999 Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research 5 257-265.
139. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B & Kerbel RS 1997 Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology 151 1523-1530.
140. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB & Slamon DJ 1994 Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 1829-1838.
141. Pietras RJ, Pegram MD, Finn RS, Maneval D & Slamon DJ 1998 Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17 2235-2249.
142. Pinkas-Kramarski R, Eilam R, Spiegler O, Lavi S, Liu N, Chang D, Wen D, Schwartz M & Yarden Y 1994 Brain neurons and glial cells express neu differentiation factor/heregulin: a survival factor for astrocytes. PNAS 91 9387-9391.
143. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ & Yarden Y 1996 Neu differentiation factor/neuregulin isoforms activate distance receptor combinations. Journal of Biological Chemistry 271 19029-19032.
144. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KH & Morin MJ 1999 Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and anti-tumor effects in athymic mice. Journal of Pharmacology and Experimental Therapeutics 291 739-748.
145. Poller DN, Spendlove I, Baker C, Church R, Ellis IO, Plowman GD & Mayer RJ 1992 Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. Journal of Pathology 168 275-280.
146. Porebska I, Harlozinska A & Bojarowski T 2000 Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumour Biology 21 105-115.
147. Prenzel N, Fischer OM, Streit S, Hart S & Ullrich A 2001 The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocrine-Related Cancer 8 11-31.
148. Prigent SA & Gullick WJ 1994 Identification of c-erbB-3 binding sites for phosphatidylinosiol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO Journal 13 2831-2841.
149. Qi C-F, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, Ciardiello F, Brandt R, Kim N, Kenney N & Salomon DS 1994 Expression of transforming growth factor alpha, amphiregulin, and cripto-1 in human breast carcinomas. British Journal of Cancer 69 903-910.
150. Rajkumar T, Stamp GW, Pandha HS, Waxman J & Gullick WJ 1996 Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB-2 and c-erbB-3 in bladder cancer. Journal of Pathology 179 381-385.
151. Ratain MJ, George CM, Janisch L, Kindler HL, Ryan C, Wood DL, Nadlr PI & Vokes EE 2002 Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proceedings of the American Society for Clinical Oncology 21 76b.
152. Riese DJ, Bermingham Y, van Raaij M, Buckley SD, Plowman GD & Stem DF 1996 Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 12 345-353.
153. Rinehart JJ, Wilding G, Willson J, Krishnamurthi S, Natale RB, Mani S, Burnett D, Olson S, Bycott P, Owens-Grillo JK, Hes M & Lenehan P 2002 A phase 1 clinical and pharmacokinetic study of oral CI-1033, a pan-ErbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proceedings of the American Society for Clinical Oncology 21 11.
154. Ruckdeschel JC, Simon G, Antonia S, Haura E, Williams C, Wagner H, Lima CR, Ettienne K, Vaughn J & Bepler G 2002 ZD1839 ('Iressa') as a single agent for the treatment of metastatic non-small-cell lung cancer. Proceedings of the American Society for Clinical Oncology 21 318.
155. Rusnak DW, Affleck K, Cockerill SG, Stubberfield G, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM & Lackey K 2001 The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Research 61 7196-7203.
156. Saeki T, Chen-Feng Q, Johnson GR, Gullick W, Tahara E, Normanno N, Ciardiello F, Kenney N, Stromberg K & Salomon DS 1992 Differential immunohistochemical localization of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Research 52 3467-3473.
157. Saeki T, Salomon DS, Normanno N, Johnson GR, Gullick WJ, Mandai K, Moriwaki S, Tahashima S, Kuniyasu M, Tahara E, Kawami H, Nishiyama M & Toge T 1994 Immunohistochemical detection of cripto-1, amphiregulin and transforming growth factor alpha in human gastric carcinomas and intestinal metaplasias. International Journal of Oncology 5 215-223.
158. Salomon DS, Brandt R, Ciardiello F & Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology 19 183-232.
159. Salomon DS, Bianco C, Ebert AD, Kahn NI, DeSantis M, Normanno N, Wechselberger C, Seno M, Williams K, Sanicola M, Foley S, Gullick WJ & Persico MG 2000 The EGF-CFC family: novel epidermal growth factor related proteins in development and cancer. Endocrine-Related Cancer 7 199-226.
160. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M & LoBuglio A 2001 Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proceedings of the American Society for Clinical Oncology 20 3.
161. Saltz L, Meropol NJ, Loehrer PJ, Waksal H, Needle M & Mayer RJ 2002 Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proceedings of the American Society for Clinical Oncology 21 127.
162. Samanta A, LaVea CM, Dougall WC, Qian X & Green MI 1994 Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. PNAS 91 1711-1715.
163. Sanidas EE, Felipe MI, Linehan J, Lemoine NR, Gullick WJ, Rajkumar T & Levison DA 1993 Expression of the c-erbB-3 gene product in gastric cancer. International Journal of Cancer 54 935-940.
164. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A & Shepard HM 1991 Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regulation 1 72-82.
165. Schlessinger J 2000 Cell signaling by receptor tyrosine kinases. Cell 103 211-225.
166. Schwartz G, Dutche JP, Vogelzang NJ, Gollob J, Thompson J, Bukowski RM, Figlin RA, Lohner M, Roskos L, Hwang CC, Foon K, Schwab G & Rowinski EK 2002 Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proceedings of the American Society for Clinical Oncology 21 24.
167. HER2 signal transduction in breast tumor cells. Journal of Biological Chemistry 266 14300-14305.
168. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodolou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanili M, Rivera E, Hortobagyi GN, Norton L & Hudis CA 2001 Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Journal of Clinical Oncology 19 2587-2595.
169. Senzer NN, Soulieres D, Siu L, Agarwala S, Vokes E, Hidalgo M, Silberman S, Allen L, Ferrante K, Fisher D, Marsolais C & Nadler P 2001 Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advance squamous cell carcinoma of the head and neck. Proceedings of the American Society for Clinical Oncology 20 2.
170. Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L, Alimandi M, Kuo A, Bacus SS, Pierce JH, Andrews GC & Yarden Y 1998 Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. Journal of Biological Chemistry 273 10496-10505.
171. Shin DM, Donato NJ, Perez-Soler R, Shin HJC, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J & Hong WK 2001 Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clinical Cancer Research 7 1204-1213.
172. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J & Arteaga CL 2002 PKB/Akt mediates cell-cycle progression by phosphorylation of p27kip1 at threonine 157 and modulation of its cellular localization. Nature Medicine 8 1145-1152.
173. Shoyab M, Plowman GD, McDonald VL, Bradley JG & Todaro GJ 1989 Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 243 1074-1076.
174. Simpson BJ, Phillips HA, Lessels AM, Langdon SP & Miller WR 1995a c-erbB growth-factor-receptor proteins in ovarian tumours. International Journal of Cancer 64 202-206.
175. Simpson BJ, Weatherill J, Miller EP, Lessels AM, Langdon SP & Miller WR 1995b c-erbB-3 protein expression in ovarian tumours. British Journal of Cancer 71 758-762.
176. Sirotnak FM, Zakowsky MF, Miller VA, Scher HI & Kris MG 2000 Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa) an inhibitor of EGFR tyrosine kinase. Clinical Cancer Research 6 4885-4892.
177. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J & Norton L 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 344 783-792.
178. Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M & Wojnar A 1998 Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Research 18 2727-2732.
179. Slichenmyer WJ, Elliot WL & Fry DW 2001 CI-1033, a pan-erbB tyrosine kinase inhibitor. Seminars in Oncology 28 80-85.
180. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM & Fox JA 1999 Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Seminars in Oncology 26 60-70.
181. Soto Parra HJ, Cavina R, Campagnoli E, Zucali P, Ginnani V, Latteri F, Ferrari B, Pedicini V, Roncalli M & Santoro A 2002 ZD1839 (Iressa) in progressive pretreated non-small-cell lung cancer (NSCLC): results from compassionate use in patients at the Istituto Clinico Humanitas, Rozzano, Milano. Proceedings of the American Society for Clinical Oncology 21 210b.
182. Sporn MB & Roberts A 1992 Autocrine secretion - ten years later. Annals of Internal Medicine 117 408-414.
183. Srinivasan R, Gillett GE, Barnes DM & Gullick WJ 2000 Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Research 60 1483-1487.
184. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E & Nesland JM 2002 EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 have different effects on survival. Journal of Pathology 196 17-25.
185. Swell JM, Macleod KG, Ritchie A, Smyth JF & Langdon SP 2002 Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD1839 ('Iressa'). British Journal of Cancer 86 456-462.
186. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P & Discafani CM 2000 Combination chemoprevention of intestinal neoplasia. Nature Medicine 6 1024-1028.
187. Tran HT, Herbst RS, Glisson BS, Pister KM, Khuri FR, Oh YW, Ordonez NG, Lee P, El-Naggar AK, Hong WK & Zinner RG 2002 Herceptin in combination with cisplatin and gemcitabine in patients with HER2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): final report of a phase II trial. Proceedings of the American Society for Clinical Oncology 21 307.
188. Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW & Ellis IO 1996 C-erbB-3 in human breast carcinoma. expression and relation to prognosis and established prognostic indicators. British Journal of Cancer 74 229-233.
189. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J & Zimmermann J 2001 Tyrosine kinase inhibitors: from rational design to clinical trials. Medicinal Research Reviews 21 499-512.
190. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ & Yarden Y 1996 A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Molecular and Cellular Biology 16 5276-5287.
191. Van Zoelen EJ, Stortelers C, Leferink AE & Van de Poll ML 2000 The EGF domain: requirements for binding to receptors of the ErbB family. Vitamins and Hormones 59 99-131.
192. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nature Medicine 8 1136-1144.
193. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ & Press M 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20 719-726.
194. Wosikowski K, Schuurhuis D, Kops GJ, Saceda M & Bates SE 1997 Altered gene expression in drug-resistant human breast cancer cells. Clinical Cancer Research 3 2405-2414.
195. Wu X, Fan Z, Masui H, Rosen N & Mendelsohn J 1995 Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. Journal of Clinical Investigation 95 1897-1905.
196. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12 1397-1403.
197. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL & Hung MC 1999 Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clinical Cancer Research 5 4164-4174.
198. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S & Arteaga CL 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Research 62 4132-4141.
199. Ye D, Mendelsohn J & Fan Z 1999 Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18 731-738.
200. You XL, Zeng-Rong N, Al Moustafa AE & Alaoui-Jamali MA 1998 Dual effects of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells. Oncogene 17 3177-3186.
201. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ & Hung MC 1998a Overexpression of ErbB-2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Molecular Cell 2 581-591.
202. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN & Hung MC 1998b Overexpression of both p185c-erbB2 and pl70mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16 2087-2094.
203. Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Bush J & Godowski PJ 1997 Neuregulin 3 (NRG3): a novel neural tissue-enriched protein that binds and activated ErbB4. PNAS 94 9562-9567.
204. Zinner RG, Donato NJ, Nemunaitis J, Cunningham CC, Shin HJ, Zentgraf RE, Ayers GD, Glisson BS, Khuri FR, Kies MS, Eiseman I, Lenehan PF, Hong WK & Shin DM 2002 Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-ErbB tyrosine kinase inhibitor, CI-1033. Proceedings of the American Society for Clinical Oncology 21 15.